Floatz logo

Rituximab

Interstitial Lung Disease

Royal Brompton & Harefield NHS Foundation Trustmonoclonal_antibodyPhase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Interstitial Lung Disease cohort.

Asset / SponsorPhaseRating
Prednisone
National Institute for Tuberculosis and Lung Diseases, Poland
Phase 4BB
Uniprost
United Therapeutics
Phase 3BB
Cyclophosphamide
Intergroupe Francophone de Cancerologie Thoracique
Phase 2/3B
Sildenafil
University of California, Los Angeles
Phase 4B
Bosentan
Royal Brompton & Harefield NHS Foundation Trust
Phase 4B

View all 34 →

Same molecule, other indications

Rituximab is also rated in:

lymphoblastic lymphomaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
grade III lymphomatoid granulomatosisDormant
BBB
Indicative · Phase 2
74 / 100
View asset →
testicular lymphomaDormant
BBB
Indicative · Phase 2
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →